Amwell (NYSE: AMWL) reported results from a large, NIMH-funded randomized trial of its SilverCloud digital behavioral health platform, published in Nature Human Behaviour. The study followed 6,205 at-risk college students over two years across 26 U.S. campuses.
Students offered SilverCloud showed 74.4% participation versus 30.2% with traditional behavioral health pathways and had 4.3% lower prevalence of any measured mental disorder at six weeks, 4.9% at six months, and 3.8% at two years. According to Amwell, this difference could correspond to about $1.18 million in avoided mental health–related costs within the study sample.
Loading…
Loading translation…
AI-generated analysis. Not financial advice.
Positive
Large independent trial: 6,205 students across 26 U.S. colleges and universities
Participation 74.4% with SilverCloud versus 30.2% with traditional behavioral health pathways
Lower prevalence of any measured mental disorder: 4.3% at six weeks, 4.9% at six months, 3.8% at two years
Estimated up to approximately $1.18 million in avoided mental health–related costs within the study sample
Benefits reported across diverse student groups, including minoritized students and those with financial stress
Students in trial
6,205 students
Clinical or high-risk levels for anxiety, depression, and/or eating disorders
Institutions involved
26 colleges and universities
U.S. higher education sites participating in the randomized trial
Students screened
Nearly 40,000 students
Screened to identify elevated mental health risk
SilverCloud participation
74.4%
Participation rate for students offered SilverCloud digital behavioral care
Traditional participation
30.2%
Participation rate with traditional behavioral health solutions
Prevalence reduction 6 weeks
4.3% lower prevalence
Any mental disorder vs. in-person care at six weeks
Prevalence reduction 2 years
3.8% lower prevalence
Any mental disorder vs. in-person care at two years
Avoided costs
$1.18 million
Estimated avoided mental health–related costs within study sample over two years
$7.58
Last Close
Volume
Volume 69,503 is 1.09x the 20-day average, indicating only modestly elevated trading.
normal
Technical
Shares at $7.58 are above the $5.61 200-day MA and trading 17.16% below the 52-week high.
AMWL is down 2.7% while peers show mixed moves: HCAT +2.59%, MNDR +1.79%, FORA +0.46%, CCLD -1.4%, SOPH -0.22%. This points to stock-specific trading rather than a clear sector trend.
Date
Event
Sentiment
Move
Catalyst
May 11
Investor conference
Neutral
-3.2%
Announcement of participation in virtual Needham technology and media conference.
May 05
Quarterly earnings
Positive
+12.4%
Reported Q1 2026 results and hosted an earnings conference call.
Apr 20
Earnings date set
Neutral
-4.5%
Scheduled Q1 2026 results release and related earnings call details.
Feb 24
Investor conference
Neutral
+0.2%
Planned appearance at TD Cowen health care conference with a fireside chat.
Feb 18
Inducement grant
Neutral
-1.7%
Grant of 61,559 RSUs to a new employee under inducement plan.
Pattern Detected
Recent history shows mixed reactions: a strong gain on earnings, but several neutral items (conference appearances, routine grants) coincided with declines, suggesting sensitivity to broader factors beyond headline tone.
Recent Company History
Over the last few months, AMWL news centered on earnings, investor conferences, and routine corporate actions. The Feb 18 inducement RSU grant and multiple conference participation announcements drew modest to negative moves, while Q1 2026 earnings on May 5 saw a strong +12.42% reaction. Today’s Nature Human Behaviour study adds clinical-scale validation for its digital behavioral health platform, contrasting with the more financial and corporate focus of prior news.
This announcement highlights large-scale, independently led evidence that Amwell’s SilverCloud program improved engagement and reduced mental disorder prevalence over up to two years, with up to $1.18 million in avoided costs within the study sample. In the context of recent earnings focused on cost discipline and visit volumes, the study adds external validation for the platform’s clinical and economic relevance. Investors may watch for future disclosures connecting such outcomes data to contracts, adoption metrics, and revenue trends.
randomized trial
technical
“National Institute of Mental Health-funded randomized trial published in Nature Human Behaviour”
A randomized trial is a study where participants are assigned by chance—like flipping a coin—to different treatments or to a comparison group so the results reflect the effect of the treatment rather than other factors. Investors care because these trials provide the most reliable evidence about whether a drug, device, or strategy works, and strong, clear results can change a company’s approval prospects, market size and risk profile quickly.
AI-generated analysis. Not financial advice.
05/18/2026 – 07:05 AM
BOSTON, May 18, 2026 (GLOBE NEWSWIRE) — Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today highlighted results from an independently led, National Institute of Mental Health-funded randomized trial published in Nature Human Behaviour examining SilverCloud® by Amwell®, the company’s digital behavioral health solution.
Conducted across 26 U.S. colleges and universities, the study included 6,205 students at clinical or high-risk levels for anxiety, depression, and/or eating disorders, making it one of the largest independent studies of its kind.
The study, led by renowned investigators from Washington University, Penn State University and University of California, Los Angeles, used a proactive care model designed to reach students before conditions worsened. Researchers screened nearly 40,000 students and offered support to those identified as being at elevated risk, rather than relying only on traditional pathways that require students to seek care on their own.
Principal Investigator Michelle G. Newman, PhD, Professor of Psychology and Psychiatry, Penn State University shares her insights on the study:
“Our goal was early detection of those at risk or meeting clinical levels for five mental health conditions, and to test whether digital mental health could move care upstream — reaching people earlier, before symptoms worsen, and doing so at population scale.”
Individuals offered SilverCloud were over twice as likely to engage:
74.4% participation with SilverCloud30.2% participation with traditional behavioral health solutions
Compared to screening and referral to in-person care, those who received digital behavioral healthcare had:
4.3% lower prevalence of having any mental disorder at six weeks4.9% lower prevalence at six months3.8% lower prevalence at two years
This positive impact was consistent across student populations, including minoritized students and those experiencing financial stress. The findings also point to the potential economic value of prevention and earlier intervention at scale.
When asked about the impact of the study, co-investigator Daniel Eisenberg, PhD, Health Economist, Professor of Health Policy and Management, UCLA said,
“The findings suggest meaningful potential economic value. Taking into account the 3.8% lower prevalence of measured mental disorders at two years, this difference could translate into up to approximately $1.18 million in avoided mental health–related costs within the study sample.”
The findings add to the evidence supporting digital mental health programs as part of a broader care strategy for higher education institutions, health plans, and other organizations seeking to expand access to clinically rigorous support. By combining proactive outreach with a structured digital intervention, the study points to a model that may help address both participation and long-term outcomes in populations with significant unmet need.
About Amwell
Amwell offers payers and health systems a single, comprehensive, technology-enabled care platform. We use technology to provide patients with better access to more convenient, affordable and effective care. The Amwell Platform includes software and services that power many clinical programs from Amwell and our growing number of partners. Our platform allows patients to experience unified, personalized and simple access to diversified clinical programs across the care continuum. As more people seek care online and more clinical programs become available, we offer integrated, future-ready, consistent solutions. The Amwell Platform is proven, operating at a large scale, enabling care for millions of patients and their sponsors while delivering dependable outcomes. For almost two decades, Amwell has proudly served some of the largest and most sophisticated healthcare organizations in the U.S. and worldwide. For more information, visit business.amwell.com or LinkedIn.
Investors:
Asher Dewhurst
Media:
FAQ
What did Amwell (NYSE: AMWL) announce about the SilverCloud study on May 18, 2026?
Amwell announced results from a large randomized trial of SilverCloud showing lower mental disorder prevalence over two years. According to Amwell, 6,205 at-risk students across 26 U.S. colleges were studied, with outcomes published in the journal Nature Human Behaviour.
How did SilverCloud by Amwell affect participation rates compared with traditional behavioral health care?
Students offered SilverCloud were more likely to engage in behavioral health care than those using traditional pathways. According to Amwell, participation reached 74.4% with SilverCloud, compared with 30.2% participation using traditional behavioral health solutions.
What impact did the SilverCloud trial report on mental disorder prevalence over two years?
The trial reported lower prevalence of any measured mental disorder for students receiving digital behavioral healthcare. According to Amwell, prevalence was 4.3% lower at six weeks, 4.9% lower at six months, and 3.8% lower at two years versus traditional referral.
What economic impact did the SilverCloud randomized study estimate for Amwell’s digital mental health care?
The study estimated potential avoided mental health–related costs within the sample due to lower disorder prevalence. According to Amwell, the 3.8% lower prevalence at two years could translate into up to approximately $1.18 million in avoided costs.
Did the SilverCloud mental health study show benefits for diverse and high-stress student groups?
Yes, the reported benefits were consistent across varied student populations, including those facing disadvantage. According to Amwell, positive impacts held for minoritized students and students experiencing financial stress within the 26-college, 6,205-participant trial.
How might SilverCloud by Amwell support colleges and health plans based on this trial?
The findings suggest SilverCloud can be part of a broader strategy to expand access to behavioral healthcare. According to Amwell, combining proactive outreach with structured digital intervention may help improve engagement and long-term mental health outcomes at scale.